| Timothy S Kristedja, MD | |
|
2001 Santa Monica Blvd Ste 560w, Santa Monica, CA 90404-2182 | |
| (310) 453-5654 | |
| (310) 453-6885 |
| Full Name | Timothy S Kristedja |
|---|---|
| Gender | Male |
| Speciality | Hematology/oncology |
| Experience | 18 Years |
| Location | 2001 Santa Monica Blvd Ste 560w, Santa Monica, California |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1881897494 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RH0003X | Internal Medicine - Hematology & Oncology | A108522 (California) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Providence Saint John's Health Center | Santa monica, CA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Providence Saint Johns Medical Foundation | 0840548624 | 315 |
News Archive
An international team of researchers including faculty at Binghamton University, State University of New York, has published a new study examining a 430,000-year-old cranium of a human ancestor that was previously described as deaf, representing the oldest case of deafness in human prehistory.
BSD Medical Corporation announced publication in Internal Medicine News Digital Network of new data from the ESHO/EORTC Soft Tissue and Bone Sarcoma Group (STBSG) Phase III clinical study of hyperthermia.
The brains of individuals with major depressive disorder appear to react more strongly when anticipating pain and also display altered functioning of the neural network that modifies pain sensitivity, according to a report in the November issue of Archives of General Psychiatry , one of the JAMA/Archives journals.
Adults with obstructive sleep apnea benefit significantly from longer nightly use of continuous positive airway pressure (CPAP), a device to improve breathing during sleep, according to a new study supported by the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health.
Incyte Corporation (NASDAQ: INCY) announced today that it has entered into a collaboration and license agreement with Novartis for two of its investigational hematology-oncology therapies: INCB18424, an oral JAK1/JAK2 inhibitor that is in Phase III development for myelofibrosis, a serious life-threatening neoplastic condition characterized by varying degrees of bone marrow failure, splenic enlargement and debilitating constitutional symptoms, and INCB28060, an oral cMET inhibitor that is about to enter Phase I development as a potential treatment for multiple cancers.
› Verified 3 days ago
| Entity Name | County Of Los Angeles |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1851363188 PECOS PAC ID: 1850296534 Enrollment ID: O20031204001218 |
News Archive
An international team of researchers including faculty at Binghamton University, State University of New York, has published a new study examining a 430,000-year-old cranium of a human ancestor that was previously described as deaf, representing the oldest case of deafness in human prehistory.
BSD Medical Corporation announced publication in Internal Medicine News Digital Network of new data from the ESHO/EORTC Soft Tissue and Bone Sarcoma Group (STBSG) Phase III clinical study of hyperthermia.
The brains of individuals with major depressive disorder appear to react more strongly when anticipating pain and also display altered functioning of the neural network that modifies pain sensitivity, according to a report in the November issue of Archives of General Psychiatry , one of the JAMA/Archives journals.
Adults with obstructive sleep apnea benefit significantly from longer nightly use of continuous positive airway pressure (CPAP), a device to improve breathing during sleep, according to a new study supported by the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health.
Incyte Corporation (NASDAQ: INCY) announced today that it has entered into a collaboration and license agreement with Novartis for two of its investigational hematology-oncology therapies: INCB18424, an oral JAK1/JAK2 inhibitor that is in Phase III development for myelofibrosis, a serious life-threatening neoplastic condition characterized by varying degrees of bone marrow failure, splenic enlargement and debilitating constitutional symptoms, and INCB28060, an oral cMET inhibitor that is about to enter Phase I development as a potential treatment for multiple cancers.
› Verified 3 days ago
| Entity Name | Providence Saint Johns Medical Foundation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1518438712 PECOS PAC ID: 0840548624 Enrollment ID: O20180810000904 |
News Archive
An international team of researchers including faculty at Binghamton University, State University of New York, has published a new study examining a 430,000-year-old cranium of a human ancestor that was previously described as deaf, representing the oldest case of deafness in human prehistory.
BSD Medical Corporation announced publication in Internal Medicine News Digital Network of new data from the ESHO/EORTC Soft Tissue and Bone Sarcoma Group (STBSG) Phase III clinical study of hyperthermia.
The brains of individuals with major depressive disorder appear to react more strongly when anticipating pain and also display altered functioning of the neural network that modifies pain sensitivity, according to a report in the November issue of Archives of General Psychiatry , one of the JAMA/Archives journals.
Adults with obstructive sleep apnea benefit significantly from longer nightly use of continuous positive airway pressure (CPAP), a device to improve breathing during sleep, according to a new study supported by the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health.
Incyte Corporation (NASDAQ: INCY) announced today that it has entered into a collaboration and license agreement with Novartis for two of its investigational hematology-oncology therapies: INCB18424, an oral JAK1/JAK2 inhibitor that is in Phase III development for myelofibrosis, a serious life-threatening neoplastic condition characterized by varying degrees of bone marrow failure, splenic enlargement and debilitating constitutional symptoms, and INCB28060, an oral cMET inhibitor that is about to enter Phase I development as a potential treatment for multiple cancers.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Timothy S Kristedja, MD 2477 Walnut Ave, Venice, CA 90291-5018 Ph: (626) 367-2824 | Timothy S Kristedja, MD 2001 Santa Monica Blvd Ste 560w, Santa Monica, CA 90404-2182 Ph: (310) 453-5654 |
News Archive
An international team of researchers including faculty at Binghamton University, State University of New York, has published a new study examining a 430,000-year-old cranium of a human ancestor that was previously described as deaf, representing the oldest case of deafness in human prehistory.
BSD Medical Corporation announced publication in Internal Medicine News Digital Network of new data from the ESHO/EORTC Soft Tissue and Bone Sarcoma Group (STBSG) Phase III clinical study of hyperthermia.
The brains of individuals with major depressive disorder appear to react more strongly when anticipating pain and also display altered functioning of the neural network that modifies pain sensitivity, according to a report in the November issue of Archives of General Psychiatry , one of the JAMA/Archives journals.
Adults with obstructive sleep apnea benefit significantly from longer nightly use of continuous positive airway pressure (CPAP), a device to improve breathing during sleep, according to a new study supported by the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health.
Incyte Corporation (NASDAQ: INCY) announced today that it has entered into a collaboration and license agreement with Novartis for two of its investigational hematology-oncology therapies: INCB18424, an oral JAK1/JAK2 inhibitor that is in Phase III development for myelofibrosis, a serious life-threatening neoplastic condition characterized by varying degrees of bone marrow failure, splenic enlargement and debilitating constitutional symptoms, and INCB28060, an oral cMET inhibitor that is about to enter Phase I development as a potential treatment for multiple cancers.
› Verified 3 days ago
Irawan Susanto, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 1223 16th St, Suite 3400, Santa Monica, CA 90404 Phone: 310-449-0939 Fax: 424-259-7790 | |
Louis Ravitz, MD Hematology & Oncology Medicare: Not Enrolled in Medicare Practice Location: 2336 Santa Monica Blvd, Suite 207, Santa Monica, CA 90404 Phone: 310-828-9311 Fax: 310-453-8533 | |
Janet Winikoff, MD Hematology & Oncology Medicare: Not Enrolled in Medicare Practice Location: 2001 Santa Monica Blvd Ste 860, Santa Monica, CA 90404 Phone: 310-828-3209 Fax: 310-828-5165 | |
Dr. Sean Dooley, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 2121 Santa Monica Blvd, Santa Monica, CA 90404 Phone: 323-829-8745 | |
Lorraine Anderson, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 1245 16th St Ste 303, Santa Monica, CA 90404 Phone: 310-481-4646 Fax: 310-899-7599 | |
Dr. Colleen Lucy Channick, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 1223 16th St Ste 3400, Santa Monica, CA 90404 Phone: 310-449-0939 | |
Carol Yukiko Nishikubo, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 2001 Santa Monica Blvd Ste 560w, Santa Monica, CA 90404 Phone: 310-453-5654 Fax: 310-453-6885 |